Disease · MONDO_0005386
peripheral arterial disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. peripheral arterial disease. Diseases, record MONDO_0005386. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005386
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Occlusive Peripheral Arterial Disease, PAD, peripheral arterial diseases, peripheral arterial disorder, peripheral artery disease
- Open Targets
- Highest stage of its drugs
- Approval, for 3 of its 111 drugs, from DailyMed, EMA Human Drugs and PMDA
- Open Targets
Drugs111
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RIVAROXABAN | CHEMBL198362 | Small molecule | Approval | EMA Human Drugs and PMDA | 8 | 5 | 5 | Drugs and targets |
| CLOPIDOGREL BISULFATE | CHEMBL1083385 | Small molecule | Approval | DailyMed | 3 | 0 | 0 | Drugs and targets |
| VORAPAXAR SULFATE | CHEMBL2107386 | Small molecule | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Phase 3 | ClinicalTrials.gov | 14 | 14 | 14 | Drugs and targets |
| CLOPIDOGREL | CHEMBL1771 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| CILOSTAZOL | CHEMBL799 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| TICAGRELOR | CHEMBL398435 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| NIACIN | CHEMBL573 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| POTASSIUM NITRATE | CHEMBL1644029 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
| SILDENAFIL | CHEMBL192 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 111
See all 111 drugsTargets161
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 5 | HMG-CoA reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 4 | Granulocyte colony stimulating factor receptor agonist | Phase 2 | https://conductscience.org/library/genes/1441 | Drugs and targets |
| P2RY12 | P2Y purinoceptor 12 | 4 | Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 negative allosteric modulator | Approval | https://conductscience.org/library/genes/64805 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 3 | Type-1 angiotensin II receptor antagonist | Phase 2 | https://conductscience.org/library/genes/185 | Drugs and targets |
| F10 | Coagulation factor X | 3 | Coagulation factor X inhibitor | Approval | https://conductscience.org/library/genes/2159 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 3 | FK506-binding protein 1A inhibitor | Phase 3 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| ADRB1 | Beta-1 adrenergic receptor | 2 | Beta-1 adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/153 | Drugs and targets |
| GUCY1A1 | Soluble guanylate cyclase | 2 | Soluble guanylate cyclase activator | Phase 2 | https://conductscience.org/library/genes/2982 | Drugs and targets |
| GUCY1A2 | Soluble guanylate cyclase | 2 | Soluble guanylate cyclase activator | Phase 2 | https://conductscience.org/library/genes/2977 | Drugs and targets |
| GUCY1B1 | Soluble guanylate cyclase | 2 | Soluble guanylate cyclase activator | Phase 2 | https://conductscience.org/library/genes/2983 | Drugs and targets |
1 to 10 of 161
See all 161 targetsTrials109
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 10 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04560998 | A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes | Phase 3 | 792 | 2025-07-08 | Diabetes Mellitus, Type 2, Peripheral Arterial Disease | SEMAGLUTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03469349 | Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB | Phase 3 | 366 | 2020-10-28 | Peripheral Arterial Diseases | ACTOVEGIN | Its record names the disease | ClinicalTrials.gov |
| NCT01408901 | Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD) | Not applicable | 210 | 2019-12-10 | Peripheral Arterial Disease | REGRAMOSTIM | Its record names the disease | ClinicalTrials.gov |
| NCT01802775 | Edoxaban in Peripheral Arterial Disease | Phase 2 | 203 | 2018-01-12 | Peripheral Arterial Disease | ASPIRIN, CLOPIDOGREL, EDOXABAN | Its record names the disease | ClinicalTrials.gov |
| NCT00403494 | A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease | Phase 2 | 190 | 2021-01-07 | Intermittent Claudication | SAPROPTERIN DIHYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01041417 | Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease | Phase 2 | 159 | 2014-12-23 | Peripheral Arterial Disease | REGRAMOSTIM | Its record names the disease | ClinicalTrials.gov |
| NCT02217501 | Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities | Phase 3 | 159 | 2021-02-21 | Peripheral Arterial Disease | ASPIRIN, CLOPIDOGREL | Its record names the disease | ClinicalTrials.gov |
| NCT02593110 | Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease | Not applicable | 114 | 2023-01-11 | Peripheral Artery Disease | TELMISARTAN | Its record names the disease | ClinicalTrials.gov |
| NCT03743636 | Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease | Phase 3 | 90 | 2025-01-14 | Peripheral Artery Disease | NICOTINAMIDE RIBOSIDE, RESVERATROL | Its record names the disease | ClinicalTrials.gov |
| NCT00587678 | Comprehensive Magnetic Resonance of Peripheral Arterial Disease | Not applicable | 85 | 2012-02-03 | Peripheral Artery Disease | EZETIMIBE, SIMVASTATIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 109
See all 109 trialsComparisons in its trials38
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Semaglutide vs Placebo: deaths from any cause | 4 of 396 | 9 of 395 | 791 | NCT04560998 | Trial comparisons |
| Semaglutide vs Placebo: serious adverse events | 74 of 396 | 78 of 395 | 791 | NCT04560998 | Trial comparisons |
| Actovegin 1200 mg vs Placebo: deaths from any cause | 0 of 184 | 0 of 182 | 366 | NCT03469349 | Trial comparisons |
| Actovegin 1200 mg vs Placebo: serious adverse events | 9 of 184 | 3 of 182 | 366 | NCT03469349 | Trial comparisons |
| Clopidogrel vs Edoxaban: Number of Adjudicated Major Adverse Cardiovascular Events During the Overall Study Period | 1 of 101 | 3 of 100 | 201 | NCT01802775 | Trial comparisons |
| Clopidogrel vs Edoxaban: Number of Participants With Amputations | 3 of 101 | 1 of 100 | 201 | NCT01802775 | Trial comparisons |
| Clopidogrel vs Edoxaban: deaths from any cause | 0 of 101 | 3 of 100 | 201 | NCT01802775 | Trial comparisons |
| Clopidogrel vs Edoxaban: Safety Assessments | 30 of 101 | 31 of 100 | 201 | NCT01802775 | Trial comparisons |
| Clopidogrel vs Edoxaban: serious adverse events | 30 of 101 | 31 of 100 | 201 | NCT01802775 | Trial comparisons |
| Sapropterin Dihydrochloride vs Placebo: deaths from any cause | 1 of 97 | 0 of 91 | 188 | NCT00403494 | Trial comparisons |
1 to 10 of 38
See all 38 comparisons in its trialsPapers from its trials89
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005386
GET https://conductscience.org/api/diseases/v1/MONDO_0005386/drugs?page=2